Compared to anti-PSMA antibodies, small-molecule PSMA inhibitors are preferable as PET imaging agents due to faster tumor uptake and more rapid excretion, which enhance contrast and reduce radiation exposure [6,7]. The gene discussed is FOLH1; the disease is neoplasm.